Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 01:58pm CEST

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.

MAIN FACTS:

- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
10:20aRECIPHARM PUBL : acquires Sanofis inhalation assets
AQ
06/22SANOFI : completes its acquisition of Ablynx following the expiration of the Squ..
AQ
06/21SANOFI : Translate Bio Announces Agreement with Sanofi Pasteur to Develop Vaccin..
AQ
06/21SANOFI : completes $3.9bn acquisition of Ablynx
AQ
06/21EVOTEC : and Sanofi sign definitive agreement to combat infectious diseases
AQ
06/21LEXICON PHARMACEUTICALS : to Present New Clinical Data at 78th American Diabetes..
AQ
06/20SANOFI : New study on Dengvaxia ill-effects boosts demand for full refund
AQ
06/20SANOFI : Completes Its Acquisition of Ablynx Following Expiration of Squeeze-Out..
AQ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19SANOFI : Recipharm buys Sanofi CMO site in UK, signs long-term supply deal
AQ
More news
News from SeekingAlpha
06/19Translate Bio Prepares For $100 Million U.S. IPO 
06/19Merger Arbitrage Mondays - June 18, 2018 
06/19Sanofi transfers infectious disease unit to Evotec 
06/19Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice Presiden.. 
06/16STOCKS TO WATCH : Don't Sleep On Vienna 
Financials (€)
Sales 2018 35 273 M
EBIT 2018 8 334 M
Net income 2018 5 099 M
Debt 2018 15 707 M
Yield 2018 4,46%
P/E ratio 2018 16,29
P/E ratio 2019 15,22
EV / Sales 2018 2,84x
EV / Sales 2019 2,69x
Capitalization 84 571 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 77,0 €
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Ameet Nathwani Executive Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-3.95%98 556
JOHNSON & JOHNSON-12.27%329 475
PFIZER0.22%213 568
NOVARTIS-9.42%191 991
ROCHE HOLDING LTD.-12.58%191 785
MERCK AND COMPANY8.90%165 373